$HOTH News
Last published 5mo ago
- 5mo agoHOTHHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense ApplicationsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19,...
- 5mo agoHOTHHoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology PlatformPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent...
- 5mo agoHOTHAI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor ArchitecturePR Newswire(NASDAQ: HOTH) ("Hoth" or the "Company") today announced that it intends to change its name to Rocket One, Inc. ("Rocket One"), and to restructure...
- 6mo agoHOTHHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer PatientsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced that it has secured regulatory authorization in...
- 7mo agoHOTHHoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted...
- 7mo agoHOTHHoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming SemaglutidePR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted...
- 7mo agoHOTHHoth Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingPR NewswireHoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical...
- 7mo agoHOTHHoth Therapeutics Announces $2.0 Million Registered Direct OfferingPR NewswireHoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical...
- 7mo agoHOTHHungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week SixPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive clinical results from its ongoing HT-001 ...
- 7mo agoHOTHHoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting TechnologyPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical...
- 7mo agoHOTHHoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug DiscoveryPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced the deployment of OpenClaw™, an advanced...
- 7mo agoHOTHHoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic AbsorptionPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) today reported positive pharmacokinetic (PK), safety, and clinical activity data for HT-001, demonstrating a...
- 8mo agoHOTHHoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD ModelPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with unmet ...
- 8mo agoHOTHHoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology ProgramPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced...
- 8mo agoHOTHHOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASESPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) today announced a significant expansion of its CLEER-001 Phase 2a clinical trial with the addition of Regis...
- 9mo agoHOTHHoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic DiseasesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced...
- 9mo agoHOTHHoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity ModelPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today...
- 9mo agoHOTHHoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency AssetsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with ...
- 9mo agoHOTHHoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer PatientsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for cancer patients with ...
- 9mo agoHOTHHoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP PositionPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced...
- 10mo agoHOTHHoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site ActivationPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing therapies for serious and underserved conditions, today ...
- 10mo agoHOTHHoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP PlatformPR NewswireHoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs, today...
- 11mo agoHOTHHoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic ProgramPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its...
- 11mo agoHOTHHoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025PR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is...
- 11mo agoHOTHHoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing CapabilitiesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced...
- 1y agoHOTHHoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver DiseasePR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and...
- 1y agoHOTHHoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven CancersPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) today highlighted FDA Orphan Drug Designation for HT-KIT and new preclinical data demonstrating >80%...
- 1y agoHOTHHoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise PlatformPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological,...
- 1y agoHOTHHoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025PR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for...
- 1y agoHOTHHoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin ToxicitiesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation treatments for dermatological and...
- 1y agoHOTHHoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company HistoryPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring...
- 1y agoHOTHHoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin ToxicitiesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application ...
- 1y agoHOTHHoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug DevelopmentPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's...
- 1y agoHOTHHoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory StandardsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple...
- 1y agoHOTHHoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in EuropePR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited...
- 1y agoHOTHHoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide BeginsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development...
- 1y agoHOTHSILOSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketGlobeNewswireTechnology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage
- 1y agoHOTHSILOHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.PR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to develop and ...
- 1y agoHOTHHoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side EffectsPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory...
- 1y agoHOTHHoth Therapeutics to host KOL Event Spotlighting HT-001, Novel TherapyPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will...
- 1y agoHOTHHoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward GrowthPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has...
- 1y agoHOTHHoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND PathwayPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapeutics for rare and inflammatory...
- 1y agoHOTHHoth Therapeutics to Attend 2025 BIO International ConventionPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of...
- 1y agoHOTHHoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell DiseasesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have...
- 1y agoHOTHHoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin ToxicitiesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for underserved conditions,...
- 1y agoHOTHHoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin ToxicitiesPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of...
- 1y agoHOTHHoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven CancersPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company developing innovative therapies for unmet medical needs, today...
- 1y agoHOTHHoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology PlatformPR NewswireHoth Therapeutics, Inc.(NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today...
- 1y agoHOTHHoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialPR NewswireHoth Therapeutics, Inc.(NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies for patients with high unmet medical...
- 1y agoHOTHHoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZPR NewswireHoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington ...